Based upon the work of
McGowan Institute for Regenerative Medicine
affiliated faculty member Joseph Glorioso III, Ph.D. (pictured), Professor in the Department of Microbiology and Molecular Genetics at the University of Pittsburgh, and Paola Grandi, Ph.D., Assistant Professor, Department of Neurological Surgery at Pitt, Oncorus, Inc. will invest in researching and developing oncolytic viral constructs which will move through preclinical development and ultimately into clinical trials. Currently, the company’s lead candidate is in preclinical development for glioblastoma multiforme (GBM). The company will also expand and improve its technology platform and accelerate the development of pipeline programs in other forms of cancer. Oncorus, Inc. recently raised $57 million in a Series A funding round.
Oncorus, Inc. is an early-stage biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers. A leader in corporate philanthropy, Oncorus has taken a pledge to donate a portion of product sales revenue to fund promising cancer research and to support cancer care in the developing world. The company is located in Kendall Square, Cambridge, Massachusetts.
Illustration: McGowan Institute for Regenerative Medicine.
Oncorus, Inc. News Release (07/19/16)
Pittsburgh Business Times (07/20/16)
Bio: Dr. Joseph Glorioso